Solid Biosciences (SLDB) Net Cash Flow Growth (3y) (2020 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 89.97% |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | -13.44% |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 33.37% |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | -29.82% |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 32.17% |
| 10 | Solid Biosciences | 713.77 Mn | 333.09 Mn | - | 194.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 194.46% |
| Dec 31, 2025 | -26.27% |
| Sep 30, 2025 | -141.30% |
| Jun 30, 2025 | 1.64% |
| Mar 31, 2025 | 131.04% |
| Dec 31, 2024 | 19.19% |
| Sep 30, 2024 | 29.81% |
| Jun 30, 2024 | 31.06% |
| Mar 31, 2024 | -27.38% |
| Dec 31, 2023 | 171.58% |
| Sep 30, 2023 | -39.57% |
| Jun 30, 2023 | -81.09% |
| Mar 31, 2023 | 33.99% |
| Dec 31, 2022 | 97.42% |
| Sep 30, 2022 | 28.77% |
| Jun 30, 2022 | -226.92% |
| Mar 31, 2022 | 32.51% |
| Dec 31, 2021 | 30.44% |
| Sep 30, 2021 | -75.97% |
| Jun 30, 2021 | -51.45% |
| Mar 31, 2021 | 0.24% |
| Dec 31, 2020 | -67.69% |
| Sep 30, 2020 | 4.03% |
| Jun 30, 2020 | -78.62% |
| Mar 31, 2020 | -45.16% |